Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Cash: 2012-2025

Historic Change in Cash for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$12.5 million.

  • Enanta Pharmaceuticals' Change in Cash fell 958.30% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.5 million, marking a year-over-year increase of 88.49%. This contributed to the annual value of -$5.5 million for FY2025, which is 88.49% up from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Change in Cash stood at -$12.5 million for Q3 2025, which was up 18.75% from -$15.4 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Change in Cash registered a high of $52.6 million during Q3 2021, and its lowest value of -$72.5 million during Q2 2021.
  • For the 3-year period, Enanta Pharmaceuticals' Change in Cash averaged around -$957,545, with its median value being -$9.8 million (2023).
  • Per our database at Business Quant, Enanta Pharmaceuticals' Change in Cash soared by 513.43% in 2021 and then slumped by 2,466.63% in 2023.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Change in Cash stood at $41.9 million in 2021, then tumbled by 104.23% to -$1.8 million in 2022, then plummeted by 2,466.63% to -$45.5 million in 2023, then skyrocketed by 203.65% to $47.1 million in 2024, then tumbled by 958.30% to -$12.5 million in 2025.
  • Its Change in Cash stands at -$12.5 million for Q3 2025, versus -$15.4 million for Q2 2025 and -$24.7 million for Q1 2025.